Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CET

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07:18p Global Influenza Market Has Been Accelerated USD 6.87 Billion in 2020
04:27p SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01:15p SANOFI : EU approval of Suliqua(TM) triggers USD 10 million milestone payment to..
12:08p Drugmakers in Davos shift focus to chronic diseases of poor
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/17 SANOFI : SuliquaTM Approved in the European Union for the Treatment of Adults wi..
01/17 SANOFI : Human Rights Day at Sanofi
01/16 SANOFI : Disclosure of trading in own shares
01/16 SANOFI : Disclosure of trading in own shares
01/13 SANOFI : MILITARY $3.2 Million Federal Contract Awarded to Sanofi Pasteur
More news
Sector news : Pharmaceuticals - NEC
10:40pDJMALLINCKRODT : to Pay $100 Million to Settle Antitrust Allegations on Unlawful D..
01:40pDJELI LILLY AND : to Buy Migraine Drug Developer CoLucid Pharmaceuticals
12:08p Drugmakers in Davos shift focus to chronic diseases of poor
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:43a Vet med industry now dominated by four firms; further mergers unlikely
08:22a New chief at Merrimack Pharma
12:21a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 MANNKIND : Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make..
01/16 PFIZER : 2 Risks Every Shareholder Should Be Aware Of
Advertisement
Financials (€)
Sales 2016 36 734 M
EBIT 2016 9 202 M
Net income 2016 5 242 M
Debt 2016 6 114 M
Yield 2016 3,85%
P/E ratio 2016 16,74
P/E ratio 2017 14,98
EV / Sales 2016 2,84x
EV / Sales 2017 2,84x
Capitalization 98 349 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,0 €
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.01%105 039
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results